JP2020526483A - 心筋節活性化剤で心不全を治療する方法 - Google Patents

心筋節活性化剤で心不全を治療する方法 Download PDF

Info

Publication number
JP2020526483A
JP2020526483A JP2019570045A JP2019570045A JP2020526483A JP 2020526483 A JP2020526483 A JP 2020526483A JP 2019570045 A JP2019570045 A JP 2019570045A JP 2019570045 A JP2019570045 A JP 2019570045A JP 2020526483 A JP2020526483 A JP 2020526483A
Authority
JP
Japan
Prior art keywords
subject
dose
csa
period
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526483A5 (enExample
Inventor
オナールプール，ナリモン
ファディ，マリク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of JP2020526483A publication Critical patent/JP2020526483A/ja
Publication of JP2020526483A5 publication Critical patent/JP2020526483A5/ja
Priority to JP2023040600A priority Critical patent/JP2023088944A/ja
Priority to JP2025121073A priority patent/JP2025165979A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019570045A 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法 Pending JP2020526483A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023040600A JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023040600A Division JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法

Publications (2)

Publication Number Publication Date
JP2020526483A true JP2020526483A (ja) 2020-08-31
JP2020526483A5 JP2020526483A5 (enExample) 2021-08-05

Family

ID=63013097

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570045A Pending JP2020526483A (ja) 2017-06-30 2018-06-29 心筋節活性化剤で心不全を治療する方法
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023040600A Pending JP2023088944A (ja) 2017-06-30 2023-03-15 心筋節活性化剤で心不全を治療する方法
JP2025121073A Pending JP2025165979A (ja) 2017-06-30 2025-07-18 心筋節活性化剤で心不全を治療する方法

Country Status (22)

Country Link
US (4) US11576910B2 (enExample)
EP (2) EP4512470A3 (enExample)
JP (3) JP2020526483A (enExample)
CN (1) CN110996953A (enExample)
AU (2) AU2018290983B2 (enExample)
BR (1) BR112019028046A2 (enExample)
CA (1) CA3068588A1 (enExample)
DK (1) DK3645002T3 (enExample)
ES (1) ES3008457T3 (enExample)
FI (1) FI3645002T3 (enExample)
HR (1) HRP20241729T1 (enExample)
HU (1) HUE069805T2 (enExample)
LT (1) LT3645002T (enExample)
MA (1) MA49508B1 (enExample)
MD (1) MD3645002T2 (enExample)
MX (2) MX2020000190A (enExample)
PL (1) PL3645002T3 (enExample)
PT (1) PT3645002T (enExample)
RS (1) RS66581B1 (enExample)
SI (1) SI3645002T1 (enExample)
SM (1) SMT202500067T1 (enExample)
WO (1) WO2019006235A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022535195A (ja) * 2019-05-19 2022-08-05 マイオカーディア，インク 収縮不全の処置
JP2023088944A (ja) * 2017-06-30 2023-06-27 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
JP2024500616A (ja) * 2020-11-12 2024-01-10 アムジェン インコーポレイテッド オメカムチブメカルビルの投与により心不全を処置する方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151786A1 (es) 2013-03-14 2015-12-11 Amgen Inc Compuestos heterociclicos y sus usos
SG10202111790YA (en) 2017-06-30 2021-12-30 Amgen Inc Synthesis of omecamtiv mecarbil
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
JP7696353B2 (ja) * 2020-02-10 2025-06-20 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
CN1296417A (zh) 1998-02-10 2001-05-23 卫福有限公司 控释制剂
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
PE20151786A1 (es) 2013-03-14 2015-12-11 Amgen Inc Compuestos heterociclicos y sus usos
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AU2018214629A1 (en) 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
MA49508B1 (fr) 2017-06-30 2024-12-31 Amgen Inc. Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
SG10202111790YA (en) 2017-06-30 2021-12-30 Amgen Inc Synthesis of omecamtiv mecarbil
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
PL3599243T3 (pl) 2018-07-26 2023-08-21 Cvie Therapeutics Limited Związki podobne do 17beta-heterocyklilu naparstnicy do leczenia niewydolności serca
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
US12442027B2 (en) 2018-12-18 2025-10-14 Amgen Inc. Method of reducing aromatic nitro compounds
BR112021017009A2 (pt) 2019-03-05 2021-11-09 Windtree Therapeutics Inc Formulação intravenosa contendo istaroxima para o tratamento da insuficiência cardíaca aguda (ahf)
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041198A4 (en) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
AU2020378197A1 (en) 2019-11-10 2022-05-26 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
JP7696353B2 (ja) 2020-02-10 2025-06-20 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
EP4243825B1 (en) 2020-11-12 2025-11-12 Amgen Inc. Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210240A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN. INVESTIG. DRUGS, vol. 25, no. 1, JPN6022026754, 2016, pages 117 - 127, ISSN: 0004812371 *
HISTORY OF CHANGES FOR STUDY: NCT02695420, SAFETY, PK, AND EFFICACY OF OMECAMTIV MECARBIL IN JAPANES, JPN6022026758, 15 May 2017 (2017-05-15), ISSN: 0005048467 *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 67, no. 12, JPN6022026753, 2016, pages 1444 - 1455, ISSN: 0004812370 *
LANCET, vol. 388, JPN6022026757, 2016, pages 2895 - 2903, ISSN: 0005048466 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023088944A (ja) * 2017-06-30 2023-06-27 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
US12295952B2 (en) 2017-06-30 2025-05-13 Cytokinetics, Inc. Methods of treating heart failure with cardiac sarcomere activators
JP2022535195A (ja) * 2019-05-19 2022-08-05 マイオカーディア，インク 収縮不全の処置
JP2024500616A (ja) * 2020-11-12 2024-01-10 アムジェン インコーポレイテッド オメカムチブメカルビルの投与により心不全を処置する方法
US12194039B2 (en) 2020-11-12 2025-01-14 Amgen Inc Methods of treating heart failure by administering omecamtiv mecarbil

Also Published As

Publication number Publication date
DK3645002T3 (da) 2024-12-16
US20250255862A1 (en) 2025-08-14
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
ES3008457T3 (en) 2025-03-24
MX2022015115A (es) 2023-01-18
MD3645002T2 (ro) 2025-04-30
AU2024200991A1 (en) 2024-03-07
MX2020000190A (es) 2020-07-22
FI3645002T3 (fi) 2025-01-29
MA49508A (fr) 2020-05-06
HRP20241729T1 (hr) 2025-03-14
HUE069805T2 (hu) 2025-04-28
JP2025165979A (ja) 2025-11-05
US12295952B2 (en) 2025-05-13
JP2023088944A (ja) 2023-06-27
AU2018290983B2 (en) 2023-11-23
MA49508B1 (fr) 2024-12-31
SI3645002T1 (sl) 2025-03-31
CN110996953A (zh) 2020-04-10
PT3645002T (pt) 2025-01-24
US11576910B2 (en) 2023-02-14
WO2019006235A1 (en) 2019-01-03
SMT202500067T1 (it) 2025-03-12
EP4512470A3 (en) 2025-04-23
AU2024200991B2 (en) 2025-04-10
US20230149394A1 (en) 2023-05-18
CA3068588A1 (en) 2019-01-03
US11931358B2 (en) 2024-03-19
EP3645002A1 (en) 2020-05-06
US20200155547A1 (en) 2020-05-21
LT3645002T (lt) 2025-02-10
EP4512470A2 (en) 2025-02-26
RS66581B1 (sr) 2025-04-30
PL3645002T3 (pl) 2025-03-24
EP3645002B1 (en) 2024-10-30
US20230355615A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
JP2020526483A (ja) 心筋節活性化剤で心不全を治療する方法
EP4243825B1 (en) Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
Von Lueder et al. New medical therapies for heart failure
US11986474B1 (en) Methods for treating heart failure by administering cardiac sarcomere activators
JP2023541766A (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
Pöss et al. Pharmacological treatment of acute heart failure: current treatment and new targets
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
CN116710139A (zh) 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
Cokkinos and Therapeutic Approaches
HK40033853B (zh) 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230315

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230317

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230406

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230411

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230502